The Journal of Wound Care (JWC) and Essity have recently published a guideline to help healthcare professionals (HCPs) overcome the challenges posed by wound infection and antimicrobial resistance (AMR), including limitations of current practice and inappropriate use of antimicrobials. This document is intended to provide that evidence‑led support for preventing and treating infection in closed surgical incisions and hard‑to‑heal wounds by presenting clinical evidence, guidance and pathways, thus supporting antimicrobial stewardship (AMS).
Introduction and evidence
The challenges of infection are greater in wounds with microbes resistant to antimicrobial treatment. Therefore, antimicrobial stewardship (AMS) guidelines are crucial in the wound care field. Below are the key facts around wound infection, antimicrobial resistance (AMR) and AMS extracted from this guideline.
Antimicrobial resistance (AMR) due to inappropriate use of antimicrobials, including topical antiseptics and systemic antibiotics, is a major concern in wound care¹⁻⁵
4.7 million
Hard‑to‑heal⁹⁻¹² and surgical wounds¹³⁻¹⁵ show increasing complications driven by antimicrobial‑resistant organisms
4.7 million
Early diagnosis and appropriate treatment are essential to reduce AMR
4.7 million
Despite the complications of AMR in wound infection, antimicrobial stewardship (AMS) principles are inconsistently applied¹⁵⁻¹⁶
4.7 million
Wound care has a widely identified need for greater antimicrobial stewardship (AMS)¹⁷⁻²¹
Implementation
The following pathways summarise the evidence‑based recommendations in the JWC guideline for treating IPC and AMS in closed surgical incisions and hard‑to‑heal wounds, including diabetes‑related foot ulcers (DRFUs) and venous leg ulcers (VLUs).
The pathways are intended as simple, easy‑to‑apply, evidence‑based tools to support and guide clinical decisions in the prevention and management of infection in surgical and
hard‑to‑heal wounds. They emphasise application of AMS principles and strategies in daily IPC practice, including a shift to early intervention with MBDs to manage microbial burden and prevent development or progression of infection.
These pathways should serve as a guide to be used in combination with clinical judgement and best‑practice guidelines. The pathways are intended to undergo clinical evaluation and validation.
click for REFERENCES